Immunomedics to Present Updated Phase II Results From Antibody-Drug Conjugate Programs at 2014 ASCO

Immunomedics to Present Updated Phase II Results From Antibody-Drug Conjugate
Programs at 2014 ASCO

MORRIS PLAINS, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
(Nasdaq:IMMU), today announced that five posters on its product candidates
will be presented at the 2014 Annual Meeting of the American Society of
Clinical Oncology (ASCO) scheduled for May 30 – June 3, 2014 at the McCormick
Place Convention Center in Chicago, Illinois.

Three of the 5 presentations will be on our antibody-drug conjugate (ADC)
programs for solid cancers, including IMMU-132, which will be featured in a
Poster Highlights Session. Presented at a separate Poster Highlights Session
will be our radiolabeled antibody for advanced pancreatic cancer,
^90Y-clivatuzumab tetraxetan, which is in a Phase III registration study in
patients with relapsed pancreatic cancer. A preclinical study on a T-cell
redirecting bispecific antibody targeting pancreatic and gastric cancers will
also be reported. Details of the presentations are listed below (all times are
in Central Time):

Sunday, June 1, 2014

  oFeasibility and results of a randomized phase Ιb study of fractionated
    ^90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer
    having two or more prior therapies (Picozzi, et al.)
    Poster Highlights Session: Gastrointestinal (Noncolorectal) Cancer
    Abstract #4026, Poster Board #45
    8:00 a.m. - 11:00 a.m.
  oEffect of interferon-α on redirected Τ-cell killing of pancreatic and
    gastric cancers (Goldenberg, et al.)
    General Poster Session: Developmental Therapeutics – Immunotherapy
    Abstract #3056, Poster Board #123
    8:00 a.m. - 11:45 a.m.
    S Hall A2
  oActivity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on
    metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I
    study (Dotan, et al.)
    General Poster Session: Developmental Therapeutics – Immunotherapy
    Abstract #3106, Poster Board #173
    8:00 a.m. - 11:45 a.m.
    S Hall A2
  oCharacterization of an anti-ΤROP-2-SN-38 antibody-drug conjugate
    (IMMU-132) with potent activity against solid cancers (Goldenberg, et al.)
    General Poster Session: Developmental Therapeutics – Immunotherapy
    Abstract #3107, Poster Board #174
    8:00 a.m. - 11:45 a.m.
    S Hall A2

Monday, June 2, 2014

  oIMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting ΤROP-2, as a
    novel platform for the therapy of diverse metastatic solid cancers:
    Clinical results (Starodub, et al.)
    Poster Highlights Session: Developmental Therapeutics - Immunotherapy
    Abstract #3032, Poster Board #24
    1:15 p.m. - 4:15 p.m.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing
monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune disorders and other serious diseases. Immunomedics' advanced
proprietary technologies allow the Company to create humanized antibodies that
can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these
technologies, Immunomedics has built a pipeline of nine clinical-stage product
candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB),
who has worldwide rights in non-cancer indications to Immunomedics' Phase III
product candidate, epratuzumab. UCB expects Phase III data in systemic lupus
erythematosus (SLE) in the first quarter of 2015. Immunomedics is exploring
epratuzumab in oncology in collaboration with outside cancer study groups.
Immunomedics' most advanced wholly owned candidate is ^90Y-clivatuzumab
tetraxetan, which is in an ongoing Phase III registration trial in patients
with pancreatic cancer. Immunomedics' portfolio of wholly owned product
candidates also includes antibody-drug conjugates (ADCs) that are designed to
deliver a specific payload of a chemotherapeutic directly to the tumor while
reducing overall toxicity effects that typically occur when these
chemotherapeutic agents are dosed alone.Immunomedics' most advanced ADCs are
IMMU-132 and IMMU-130, which are in Phase I/II trials for a number of solid
tumors and metastatic colorectal cancer (mCRC), respectively. Immunomedics
also has a number of other product candidates that target solid tumors and
hematologic malignancies, as well as other diseases, in various stages of
clinical and pre-clinical development. These include bispecific antibodies
which have application as T-cell redirecting immunotherapies targeting cancers
and infectious diseases as well as next-generation therapies in cancer and
autoimmune disease. Immunomedics creates these bispecific antibodies using its
patented DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The Company
believes that its portfolio of intellectual property, which includes
approximately 248 active patents in the United States and more than 400
foreign patents, protects its product candidates and
technologies.Immunomedics' strength in intellectual property has resulted in
the top-4 ranking in the January 2014 Patent Board scorecard in the
Biotechnology industry.For additional information on the Company, please
visit its website at The information on its website does
not, however, form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials (including the funding therefor, outcomes, timing or associated costs),
out-licensing arrangements (including the timing and amount of contingent
payments), forecasts of future operating results, potential collaborations,
and capital raising activities, involve significant risks and uncertainties
and actual results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are not limited
to, new product development (including clinical trials outcome and regulatory
requirements/actions), our dependence on UCB for the further development of
epratuzumab for non-cancer indications, risks associated with the outcome of
pending litigation, competitive risks to marketed products and availability of
required financing and other sources of funds on acceptable terms, if at all,
as well as the risks discussed in the Company's filings with the Securities
and Exchange Commission.The Company is not under any obligation, and the
Company expressly disclaims any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future
events or otherwise.

CONTACT: Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.